HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance

  • Leukemia. 2010 Oct;24(10):1807-9. doi: 10.1038/leu.2010.169.
H Luo ,  H Quan ,  C Xie ,  Y Xu ,  L Fu ,  L Lou
PMID: 20703259 DOI: 10.1038/leu.2010.169
Products